HLX11

HLX11, now marketed as Poherdy (pertuzumab-dpzb), is Shanghai Henlius Biotech's biosimilar of Roche's Perjeta and became the first FDA-approved interchangeable pertuzumab biosimilar in the United States on 13 November 2025 [6]. The EMA's CHMP adopted a positive opinion on 26 February 2026, with European Commission marketing authorization expected roughly 67 days later [7]. The Phase 3 equivalence study NCT05346224 [2] met its primary endpoint of pathological complete response in September 2024 [3], enabling the BLA and MAA. Organon holds ex-China commercialization rights under a 2022 partnership [6]. Perjeta generated approximately CHF 4 billion in 2023 sales for Roche [5], but the commercial thesis is complicated by Roche's rapid conversion of that franchise to subcutaneous Phesgo, which grew 48 percent to CHF 2.4 billion in 2025 while Perjeta IV declined 13 percent [8]. Roche and Genentech sued Henlius and Organon in August 2025 alleging Perjeta patent infringement, and that litigation remains open [9].

HLX11 (pertuzumab-dpzb, brand name Poherdy) is an approved biosimilar of pertuzumab, not a novel compound. It followed the 351(k) regulatory pathway in the US and the equivalent biosimilar pathway in Europe. Biosimilars do not receive breakthrough, fast track, or orphan designations, since those apply to novel investigational drugs. Development milestones: a completed Phase 1 study in healthy male volunteers showed comparable pharmacokinetics, immunogenicity, and safety versus US-, EU-, and CN-approved pertuzumab [1]. The Phase 3 confirmatory equivalence study NCT05346224 [2] met its primary endpoint of total pathological complete response in September 2024 [3]. The FDA approved Poherdy on 13 November 2025 as the first interchangeable pertuzumab biosimilar, meaning it can be substituted at the pharmacy without prescriber intervention where state law permits [6]. The EMA CHMP issued a positive opinion on 26 February 2026, and European Commission marketing authorization is expected around late April or early May 2026 for all reference-product indications [7]. Henlius's biosimilar track record includes prior approvals of trastuzumab biosimilar Zercepac (HLX02), which received European Commission marketing authorization in July 2020 following the May 2020 CHMP positive opinion, plus biosimilars of rituximab, adalimumab, and bevacizumab. Organon commercializes Poherdy globally outside China under a 2022 license and supply agreement [6].

Pertuzumab, and by extension HLX11, is an antibody that grabs onto HER2, a growth-signal receptor on the surface of breast cancer cells. HER2 (encoded by ERBB2) is a receptor that drives cell division when it pairs with itself or with related receptors like HER3. In roughly 15 to 20 percent of breast cancers, tumor cells make far too much HER2, and the constant growth signal fuels aggressive disease. Trastuzumab (Herceptin) was the first drug to block this signaling by binding one region of HER2. Pertuzumab binds a different region, the dimerization arm, which physically prevents HER2 from pairing with HER3, the pairing that produces the strongest downstream growth signal. When trastuzumab and pertuzumab are used together, they cover two escape routes, and the combination plus chemotherapy became standard-of-care for HER2-positive metastatic and early breast cancer after the CLEOPATRA [3a] and APHINITY [4] trials. The mechanism is one of the most rigorously validated in oncology. For a biosimilar, the biology question is not whether HER2 dimerization blockade works, but whether HLX11 binds HER2 with the same affinity, engages the same immune effector functions such as antibody-dependent cellular cytotoxicity, and delivers a clinical result statistically indistinguishable from branded pertuzumab. Interchangeability, which the FDA granted at initial approval, additionally requires demonstration that switching between reference and biosimilar does not increase safety or efficacy risk relative to staying on reference alone.

NCT05346224 [2] was a Phase 3 randomized, double-blind equivalence study in patients with HER2-positive, hormone-receptor-negative early-stage or locally advanced breast cancer. Patients received neoadjuvant HLX11 or EU-sourced Perjeta, both combined with trastuzumab and docetaxel, before surgery. The primary endpoint was the total pathological complete response rate (tpCR) at surgery as assessed by an Independent Review Committee, meaning no residual invasive cancer in the breast or lymph nodes. Equivalence was judged by whether the confidence interval for the tpCR risk difference fell within pre-specified margins. Henlius announced the primary endpoint was met on 30 September 2024, with the tpCR rate confidence interval falling within the pre-specified equivalence margin [3]. Enrollment target and estimated primary completion date from ClinicalTrials.gov could not be reliably retrieved via web search at the time of this revision, and readers should consult the registry entry directly for exact figures. The HR-negative restriction was deliberate: hormone-receptor status affects pCR rates (HR-negative tumors tend to achieve higher pCR), and holding HR status constant reduces variance and tightens the equivalence bounds. Design details align with regulatory expectations: EMA and FDA guidance both accept neoadjuvant pCR as a valid endpoint for pertuzumab biosimilar equivalence given the mechanism-driven pathological readout. The Phase 1 comparability data across US, EU, and Chinese reference pertuzumab products [1] supported multi-region submissions on a single Phase 3 dataset, and the FDA and EMA both accepted the resulting filings.

Our model estimates a 11% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase; it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Regulatory risk is essentially resolved. FDA interchangeable approval landed November 2025 [6] and EMA CHMP issued a positive opinion February 2026 [7], leaving only the routine European Commission step. The primary open risks are now commercial and legal. Legal risk is concrete: Roche and Genentech sued Henlius and Organon in August 2025 alleging infringement of Perjeta-related patents, and the litigation remains active as of this revision [9]. An adverse injunction could delay US launch or force a settlement with royalties or a defined market-entry date. Commercial risk is the dominant question. Roche has aggressively converted the Perjeta franchise to subcutaneous Phesgo (fixed-dose pertuzumab plus trastuzumab plus hyaluronidase). In 2025 Phesgo sales rose 48 percent to CHF 2.4 billion while Perjeta IV declined 13 percent [8], indicating a majority of the branded HER2 dual-blockade market has already moved to a subcutaneous, coformulated product that no current pertuzumab biosimilar can directly substitute for. An IV pertuzumab biosimilar therefore competes for a shrinking pool. Safety risk is low for a well-characterized biologic copy: pertuzumab toxicities (diarrhea, rash, and cardiac dysfunction in combination with trastuzumab) are established, and Poherdy should mirror this profile. Competitive risk within the biosimilar class is limited near-term because Poherdy is currently the only FDA-approved pertuzumab biosimilar. Alvotech, Celltrion, and Samsung Bioepis programs remain in development or under review, but Poherdy's interchangeable designation is a durable formulary advantage, since pharmacists can substitute it without prescriber contact in permissive states. EU SPC expiry for pertuzumab could not be pinned to a specific year via public sources during this revision, and the Roche 2025 US patent challenges [9] indicate active exclusivity remains at issue in the US as well; readers requiring precision should consult the European Patent Office SPC register and the docket for the Roche v. Henlius/Organon case.

Reclassify. HLX11 should no longer sit in the pipeline node set; it is an approved product as of November 2025 (FDA) with EMA authorization imminent. The BioCosm PoS model output for this node is invalid because the pipeline base_rate_v1 model has no biosimilar node type. Fixing the underlying data quality issue matters more than the individual writeup: the same defect will misprice every biosimilar in the corpus. For the asset itself, the story is now commercial and legal, not clinical. Poherdy is the first and only interchangeable pertuzumab biosimilar in the US, which gives it a real formulary edge, but the addressable IV pertuzumab market is structurally impaired by Roche's Phesgo conversion (Phesgo was CHF 2.4 billion and growing 48 percent in 2025 versus Perjeta IV declining 13 percent [8]). The Roche/Genentech patent suit filed August 2025 [9] is the single most important near-term risk: an injunction or unfavorable settlement could delay Organon's US launch cadence. Watch for: (1) European Commission final marketing authorization (~April/May 2026, following the February CHMP opinion [7]); (2) Roche v. Henlius/Organon docket updates and any Markman ruling or settlement; (3) Organon quarterly disclosures for Poherdy launch revenue and formulary wins; (4) Roche quarterly reports for continued Phesgo vs Perjeta split; (5) advancement of Alvotech, Celltrion, and Samsung Bioepis pertuzumab biosimilars, which would erode Poherdy's monopoly biosimilar status. The BioCosm data pipeline should also open a company-level view of Henlius given the multi-biosimilar franchise (Zercepac plus Poherdy plus adalimumab/rituximab/bevacizumab).